BioNTech shares are trading higher, rebounding after the stock dipped on Friday following positive data from Pfizer’s COVID-19 oral antiviral treatment candidate, which weighed on vaccine names.

by | Nov 8, 2021 | Uncategorized | 0 comments

Submit a Comment Cancel reply

Your email address will not be published. Required fields are marked *

Comment

Name *

Email *

Website

Save my name, email, and website in this browser for the next time I comment.